Related references
Note: Only part of the references are listed.Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
Sabrina Paganoni et al.
ANNALS OF NEUROLOGY (2022)
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis
Simon Witzel et al.
JAMA NEUROLOGY (2022)
Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis
Arpan R. Mehta et al.
ACTA NEUROPATHOLOGICA (2021)
Trials for neurodegenerative diseases: time to innovate
Arpan R. Mehta et al.
LANCET NEUROLOGY (2021)
Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective
Charis Wong et al.
BRAIN COMMUNICATIONS (2021)
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
Jesus S. Mora et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2020)
Adding new experimental arms to randomised clinical trials: Impact on error rates
Babak Choodari-Oskooei et al.
CLINICAL TRIALS (2020)
Design, analysis and reporting of multi-arm trials and strategies to address multiple testing
Ayodele Odutayo et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)
Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification
Richard A. Parker et al.
CLINICAL TRIALS (2020)
TRICALS: creating a highway toward a cure
Ruben P. A. van Eijk et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2020)
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
Leonard H. van den Berg et al.
NEUROLOGY (2019)
Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
Ruben P. A. van Eijk et al.
NEUROLOGY (2019)
Machine learning algorithms for systematic review: reducing workload in a preclinical review of animal studies and reducing human screening error
Alexandra Bannach-Brown et al.
SYSTEMATIC REVIEWS (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
Christopher Crockford et al.
NEUROLOGY (2018)
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
R. J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
Peter Connick et al.
BMJ OPEN (2018)
Living systematic review: 1. Introduction-the why, what, when, and how
Julian H. Elliott et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2017)
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
Koji Abe et al.
LANCET NEUROLOGY (2017)
Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols
Mahesh K. B. Parmar et al.
CLINICAL TRIALS (2017)
Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice
Mark Halliday et al.
BRAIN (2017)
Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis
Hanna M. Vesterinen et al.
PLOS ONE (2015)
Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models
Hyung-Jun Kim et al.
NATURE GENETICS (2014)
The PRO-ACT database Design, initial analyses, and predictive features
Nazem Atassi et al.
NEUROLOGY (2014)
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
An-Wen Chan et al.
ANNALS OF INTERNAL MEDICINE (2013)
Neuroprotective Effects of Psychotropic Drugs in Huntington's Disease
Edward C. Lauterbach
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study
Julie Phukan et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
A pilot trial of memantine and riluzole in ALS: Correlation to CSF biomarkers
Todd D. Levine et al.
AMYOTROPHIC LATERAL SCLEROSIS (2010)
A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis
Mamede De Carvalho et al.
AMYOTROPHIC LATERAL SCLEROSIS (2010)
Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial
Petra Kaufmann et al.
AMYOTROPHIC LATERAL SCLEROSIS (2007)
Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model
RG Wang et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2005)
Frontotemporal dementia: A randomised, controlled trial with trazodone
F Lebert et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2004)
Share Paper
